| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -11.0 | -11.9 |
| EPS (diluted, $ a share) | $-0.46 | $-0.64 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: KLRS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Kalaris Therapeutics, Inc.: key numbers
- Share price
- $1.43Close, Nov 17
- Market cap
- $34M
- Shares outstanding
- 23.8MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Kalaris Therapeutics, Inc.
All →Kalaris Therapeutics Financial Results
Kalaris Therapeutics reported third quarter 2026 financial results, ending the period with $82.9 million in cash and marketable securities. The company announced a delay in its Phase 1b/2 study of TH103 for nAMD due to a manufacturing supply interruption, with preliminary data now expected in the second half of 2027. Despite the delay, the company successfully completed a technology transfer to a commercial-scale manufacturer and extended its cash runway into 2028.
- Term
- Q3 2026
“Kalaris made meaningful progress in the third quarter. We continue to enroll and dose nAMD patients in the ongoing Phase 1b/2 study. In addition to progressing the clinical trial, we have successfully completed the tech transfer to a new commercial-scale manufacturer, with initial test batches achieving the target specifications. Given the paramount importance of ensuring critical quality attributes at the scale required for Phase 3 and commercial supply, this was a significant accomplishment in Q3 and strengthens our confidence in our future clinical supply.”
Andrew Oxtoby, Chief Executive Officer